Matteo Canale

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 297 citations · Full text

Medicine, Oncology, Pharmacology +16

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer

Paola Ulivi, Matteo Canale, Alessandro Passardi et al. · International Journal of Molecular Sciences · 2018 · 74 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Journal of Clinical Medicine · 2020 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma

Leticia Colyn, Marina Bárcena‐Varela, Gloria Álvarez‐Sola et al. · Hepatology · 2020 · 66 citations

Medicine, Molecular Biology, Oncology +17

Sulodexide Down-Regulates the Release of Cytokines, Chemokines, and Leukocyte Colony Stimulating Factors from Human Macrophages: Role of Glycosaminoglycans in Inflammatory Pathways of Chronic Venous Disease

Ferdinando Mannello, Daniela Ligi, Matteo Canale et al. · Current Vascular Pharmacology · 2014 · 64 citations

Life Sciences, Immunology, Pharmacology +17